Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation
about
Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugsFlexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulationsDiscovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ ReductionNMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexesFunction, therapeutic potential and cell biology of BACE proteases: current status and future prospects.BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's diseaseAlzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS).Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery.Novel γ-secretase modulators: a review of patents from 2008 to 2010.Fragment informatics and computational fragment-based drug design: an overview and update.Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).Advances in the identification of β-secretase inhibitors.The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927.Creation of Novel Cores for β-Secretase (BACE-1) Inhibitors: A Multiparameter Lead Generation Strategy.Silencing of amyloid precursor protein expression using a new engineered delta ribozyme.One-pot synthesis of 2-amino-indole-3-carboxamide and analogous.Fragment-based Binding Efficiency Indices in Bioactive Molecular Design: A Computational Approach to BACE-1 Inhibitors.Factors Influencing the Potency of Alzheimer Inhibitors: Computational and Docking Studies.Effect of sampling on BACE-1 ligands binding free energy predictions via MM-PBSA calculations.Synthesis of amino heterocycle aspartyl protease inhibitors.Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer's Disease.
P2860
Q26740189-89614AA4-CAC9-45A3-B50A-0EF7DADF908CQ27676370-ABF21BFD-FCCA-4713-9945-526A8CB8230DQ27676383-065133D2-6A60-4793-AC9E-8CB461533420Q30366295-56D84F4F-1837-4B53-BC57-62F620EEC36EQ33862796-7CFEF789-F8BF-42FC-AC5A-F5AEB49BFAD4Q34156758-B0FFA525-46C9-4101-B2F2-802BDDEA6002Q34767547-78ECC2B4-C29E-4A38-BCBF-ADD7510FEF75Q35758963-CCF88DA9-23D7-4D2C-B0CE-07717C6B1FC4Q36269125-A45D3BFB-93DE-4588-9CF2-C6871B879CDBQ37828163-CC224789-392C-495A-8DE8-56B795AE8E29Q37995087-07CB4731-F791-44E7-B6CE-A88635523156Q38003497-C586E6D9-F702-4E58-88FA-D94FFAE5368DQ38097074-B01FE2CA-54A6-40C4-8189-A1264568196BQ38127826-72271FB3-ECDF-4572-9F57-44C2A770F113Q39222469-9617F165-47F3-4615-A997-F4790E633B4CQ39244962-D44DE9BC-936A-4EB7-B92B-D9A8D03EAE08Q39786441-ADDC2820-7CC9-4F03-8068-AFD6A2D6393CQ41841425-D161CD2F-43B8-4C95-9319-6CD857768587Q42775745-51AC3678-24B9-470A-B951-874DD641B601Q42927405-5180D31C-9564-4478-AC12-F4FC7323CBEEQ47208919-7BE4E69D-9F58-4D68-BEE5-1F5669B5BF5EQ48022145-CED6BACA-D038-4490-AB70-5CB9272426EAQ50856369-00654EB7-39FC-4FA1-8EB1-2E3317889696Q54940167-3CFE292F-33D2-44E5-8674-7E67DB0AF25DQ55428413-53F26401-95EE-49CC-81EB-7BF2200EEC12
P2860
Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Discovery of cyclic acylguanid ...... nhibitor design and validation
@ast
Discovery of cyclic acylguanid ...... nhibitor design and validation
@en
Discovery of cyclic acylguanid ...... nhibitor design and validation
@nl
type
label
Discovery of cyclic acylguanid ...... nhibitor design and validation
@ast
Discovery of cyclic acylguanid ...... nhibitor design and validation
@en
Discovery of cyclic acylguanid ...... nhibitor design and validation
@nl
prefLabel
Discovery of cyclic acylguanid ...... nhibitor design and validation
@ast
Discovery of cyclic acylguanid ...... nhibitor design and validation
@en
Discovery of cyclic acylguanid ...... nhibitor design and validation
@nl
P2093
P50
P3181
P356
P1476
Discovery of cyclic acylguanid ...... nhibitor design and validation
@en
P2093
Andrew Stamford
Brian A McKittrick
Daniel F Wyss
Elizabeth M Smith
Eric Parker
Jared Cumming
Jesse Wong
Johannes Voigt
John C Hunter
Lingyan Wang
P304
P3181
P356
10.1021/JM901408P
P407
P577
2010-02-11T00:00:00Z